

## Richard Haynes

---

**From:** Heather House <heather.house@admin.ox.ac.uk>  
**Sent:** 06 July 2021 15:16  
**To:** Richard Haynes  
**Cc:** Peter Horby; Martin Landray; Joseph Butchinsky; oxfordjro@mail.studyline.uk.com  
**Subject:** Randomised Evaluation of COVID-19 Therapy (RECOVERY); EudraCT 2020-001113-21, SA 18  
**Attachments:** 281712\_Substantial Amendment 18\_.pdf

Dear Richard

I can confirm that the above referenced substantial amendment has been reviewed in CTRG and we are happy for it to be submitted to the relevant organisations for approval. This email can be forwarded as confirmation of sponsor approval for the amendment as required.

Please find attached the PDF version of the signed and locked amendment tool.

In order to ensure validation of your submission by the relevant organisations, please submit both tracked and clean copies of all amended documents and copy in the CTRG generic email address (ctr@admin.ox.ac.uk) so the Sponsor has final documents and is included in subsequent correspondence.

Please make your MHRA submission, through the MHRA submission platform.

Please send a copy of the approval letter to the CTRG generic email address (ctr@admin.ox.ac.uk) once you have received them. Please do not implement your amendment until all approvals are in place.

Best wishes

Heather

PID14892-A021-SP001-AC001

### Heather House

Head of Clinical Research Support  
(University Lead of the Joint Research Office)  
Research Services  
University of Oxford  
Joint Research Office  
1<sup>st</sup> Floor, Boundary Brook House  
Churchill Drive  
Headington  
Oxon, OX3 7GB

✉ Email: [heather.house@admin.ox.ac.uk](mailto:heather.house@admin.ox.ac.uk)  
[www.admin.ox.ac.uk/researchsupport](http://www.admin.ox.ac.uk/researchsupport)



Guidance (FAQs) for Clinical Research during the COVID-19 national emergency can be found on:  
<https://researchsupport.admin.ox.ac.uk/ctrq>